0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Alteration of methylation status in the ATXN3 gene promoter region is linked to the SCA3/MJD.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          DNA methylation has been acknowledged as one of the key epigenetic mechanisms involved in the regulation of gene expression and genomic functions. Alteration of the DNA methylation level has been linked to modification of the disease progression and instability regulation of certain disease-causing repeats in neurodegenerative diseases. In this study, blood samples collected from spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD) patients versus control were used to explore the potential link of DNA methylation levels at ATXN3 gene promoter to the pathogenesis of SCA3/MJD. We found that the methylation levels in the ATXN3 promoter were significantly higher in SCA3/MJD patients relative to the controls. Furthermore, higher methylation levels were detected in the SCA3/MJD patients with earlier age at onset and the families with an intergenerational CAG repeats instability. In addition, the first CpG island of the ATXN3 promoter served as the main regulation region of DNA methylation. These findings suggested that an epigenetic change may contribute to the pathogenesis of the SCA3/MJD and provide potential therapeutic targets for CAG repeats-based diseases.

          Related collections

          Author and article information

          Journal
          Neurobiol. Aging
          Neurobiology of aging
          Elsevier BV
          1558-1497
          0197-4580
          May 2017
          : 53
          Affiliations
          [1 ] Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China.
          [2 ] State Key Laboratory of Medical Genetics, Central South University, Changsha, Hunan, P. R. China.
          [3 ] School of Information Science and Engineering, Central South University, Changsha, Hunan, P. R. China.
          [4 ] Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China; State Key Laboratory of Medical Genetics, Central South University, Changsha, Hunan, P. R. China; Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, Hunan, P. R. China.
          [5 ] Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China; State Key Laboratory of Medical Genetics, Central South University, Changsha, Hunan, P. R. China; Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, Hunan, P. R. China. Electronic address: jianghong73868@126.com.
          Article
          S0197-4580(16)30327-X
          10.1016/j.neurobiolaging.2016.12.014
          28094059
          858fab66-6faf-4f9e-a343-c7112e5e4128
          History

          ATXN3 promoter,Anticipation,DNA methylation,DNMT1,Dynamic mutation,SCA3/MJD

          Comments

          Comment on this article